All In Biotech

Drug Trial Radar · NCT07059221

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

A Multicenter, Open-label Phase Ib/II Clinical Trial of SHR-A2102 Injection in Combination With Adebrelimab Injection, With or Without Other Anti-tumor Therapies, in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Jul 11, 2025

Primary completion

Mar 2027

Study completion Mar 2029

Sponsor

Sponsor type
Industry
First posted
Jul 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102/SHR-9839(sc) for Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Conditions

  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

  • SHR-A2102Drug

    Administration by intravenous infusion

  • AdebrelimabDrug

    Administration by intravenous infusion

  • CetuximabDrug

    Administration by intravenous infusion

  • SHR-9839(sc)Drug

    Administration by Subcutaneous injection

  • Carboplatin / CisplatinDrug

    Administration by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RP2DTime frame: through phase IB completion, an average of 5 years
  2. Incidence and severity of AE(DLT)Time frame: from Day1 to 90 days after last dose
  3. ORRTime frame: 5 years after the last subject was enrolled in the group

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.